The purpose of this study is to assess the safety, tolerability and efficacy of JPI-547 in combination with modified FOLFIRINOX (mFOLFIRINOX) or Gemcitabine-nab-paclitaxel (GemAbraxne) in patients with locally advanced and metastatic pancreatic cancer
Histologically or cytologically confirmed inoperable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC)
Those with at least one measurable lesion in accordance with RECIST 1.1
Those with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Those with an expected survival period ≥12 weeks
Those with a history of severe hypersensitivity to the investigational product or combination anticancer drugs.
Those with the following medical history or surgical history/procedural history confirmed
Other primary malignant tumors other than pancreatic cancer
Major surgery that requires general anesthesia or breathing aid